Physician profile
Lude Xue
NPI 1649988692
$793.14
in general payments reported to CMS, 2019-2025
14 companies · $62.53 in 2025
The $62.53 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $286 · 2024: $445 · 2025: $62.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $608 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.19 |
| Education | $184.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $303.07 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $99.43 | 2023-2024 | |
| Channel Medsystems, INC. | $69.00 | 2023 | |
| Exeltis, USA INC. | $54.72 | 2023-2024 | Slynd |
| Millicent US INC | $46.33 | 2024 | Intrarosa |
| Abbvie INC. | $40.61 | 2023 | |
| Medtronic, INC. | $38.79 | 2023 | Interstim |
| Gynesonics, INC. | $35.42 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Sumitomo Pharma America, INC. | $33.09 | 2024 | Myfembree |
| Shield Therapeutics INC | $17.52 | 2024 | |
| Pfizer INC. | $17.14 | 2024 | |
| Hologic Sales and Service, LLC | $15.00 | 2024 | Aptima |
| Biogen, INC. | $14.64 | 2025 | Zurzuvae |
| Organon LLC | $8.38 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lude Xue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.